The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Gemcitabine plus oxaliplatin (GemOx) in advanced hepatocellular carcinoma (HCC): A multicenter study of over 200 patients.
N. Williet
No relevant relationships to disclose
A. Zaanan
No relevant relationships to disclose
M. Hebbar
No relevant relationships to disclose
V. Boige
No relevant relationships to disclose
L. Fartoux
No relevant relationships to disclose
T. Mansourbakht
No relevant relationships to disclose
O. Dubreuil
No relevant relationships to disclose
O. Rosmorduc
No relevant relationships to disclose
F. Bonnetain
No relevant relationships to disclose
J. Taïeb
No relevant relationships to disclose